FarmaMondo Hong Kong Limited confirms the approval of the reimbursement for Carbaglu (Carglumic Acid) dispersible tablets, on behalf of Recordati Rare Diseases in Hong Kong.
Carbaglu (Carglumic Acid) is indicated in treatment of hyperammonaemia due to N-acetylglutamate synthase (NAGS) primary deficiency, hyperammonaemia due to methymalonic acidaemia (MMA), hyperammonaemia due to propionic acidaemia (PA).
The reimbursement achieved will grant access to all patients in HK to this essential medicine.
Yaron Spigel, Group Chief Executive Officer of Farma Mondo, commented:
“We are proud to strengthen our partnership with Recordati Rare Diseases for the benefit of children and adults with hyperammonemia due to NAGS primary deficiency and due to MMA and PA in Hong Kong. To give access to these patients is a new success for our local team and strengthen our relationship with Recordati Rare disease. It demonstrates FarmaMondo’s continued commitment to widening access to essential lifesaving medicines in emerging and established markets”
About Farma Mondo Group
Farma Mondo is a fast-growing Swiss group dedicated to providing Biopharma, healthcare professionals and their patients around the world with greater access to medicines, and in the process increasing the value of a pharmaceutical product by extending and expanding its lifecycle. The Group offers high value market access and specialty distribution services, through a unique infrastructure and geographical footprint, targeted to enable patient access to Specialty Medicines in key Emerging Markets through a combined approach of Named Patient access and full commercialization.
For more details, please visit https://farmamondo.com/
About Recordati Rare Diseases
Recordati Rare Diseases forms part of the Recordati Group. Recordati is an international pharmaceutical group listed on the Italian Stock Exchange (XMIL: REC), with roots dating back to a family-run pharmacy in Northern Italy in the 1920s. We are uniquely structured to provide treatments across specialty and primary care, and rare diseases. Our fully integrated operations span clinical development, chemical and finished product manufacturing, commercialization and licensing. We operate in approximately 150 countries across EMEA, the Americas and APAC with over 4,450 employees. We believe that health is a fundamental right, not a privilege. Today, our purpose of “unlocking the full potential of life” aims at empowering individuals to live life to the fullest, whether addressing common health challenges or the rarest.
For more information, visit https://recordatirarediseases.com
